BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech)

N/A

Report date: 2025/06/27 14:45:00

Base Information

Drug NameBCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech)
Drug Alias NameBCMA/GPRC5D targeting CAR-T cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsG-protein coupled receptor family C group 5member D modulators
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A